Due to concerns related to treatment with erythropoietin (EPO) and possible negative effects on tumour control, a workshop was organised by the Medical Products Agency of Sweden with the aim to revise national treatment guidelines if needed. In patients with solid tumours, conflicting results have been reported with respect to tumour control and survival. Until further notice it is therefore recommended that EPO should be used restrictively in the treatment of patients with cancer and that the anticipated improvement in quality of life should be evaluated against potential risks.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s12032-007-0037-5 | DOI Listing |
Publication Analysis
Top Keywords
tumour control
8
erythropoietin therapy
4
therapy cancer
4
cancer anaemia
4
anaemia updated
4
updated swedish
4
swedish recommendations
4
recommendations concerns
4
concerns treatment
4
treatment erythropoietin
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!